Form 4: Prelude Therapeutics Director Dier Mardi Acquires Stock Options

Director Dier Mardi acquired 23,500 stock options in Prelude Therapeutics on June 14, 2024.

Summary

• Director Dier Mardi acquired 23,500 stock options of Prelude Therapeutics on June 14, 2024.
• The exercise price of the options is $3.90.
• The options expire on June 13, 2034.
• The options will fully vest upon the earlier of the Issuer's next annual stockholder meeting, or the one-year anniversary of the grant date, subject to the Reporting Person's provision of service to the Issuer on each vesting date.

Sentiment

Score: 6

Explanation: The sentiment is neutral. It's a routine transaction, but director ownership is generally viewed as a positive signal.

Positives

• The acquisition of stock options by a director can be seen as a positive sign, indicating confidence in the company's future performance.

Future Outlook

The options will fully vest upon the earlier of (a) the Issuer's next annual stockholder meeting, or (b) the one-year anniversary of the grant date, subject to the Reporting Person's provision of service to the Issuer on each vesting date.

Industry Context

This is a standard SEC Form 4 filing, reflecting a change in beneficial ownership of securities. It is common for directors and officers of publicly traded companies to receive stock options as part of their compensation.

Stakeholder Impact

• The acquisition of stock options by a director could have a slightly positive impact on shareholder sentiment.

Key Dates